ABION Inc.

203400· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩719+4.51%

2026-08-04

Financials

Valuation Metrics

ABION Inc.'s Market Cap is ₩648B. At end of 2025 it was ₩2820B. Ranked #1562 of 2,436 in KR market (top 64%), #912 of 1,649 on KOSDAQ (top 55%), #175 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	64.78B KRW	KR#1,562/2,436 Sec#175/234
Revenue	1.01B KRW	KR#2,391/2,436 Sec#219/234
Net Income	-25.20B KRW	KR—/2,436 Sec—/234
Total Assets	73.80B KRW	KR#1,957/2,436 Sec#165/234
Net Assets	61.86B KRW	KR#1,728/2,436 Sec#151/234
Employees	44	KR#2,074/2,436 Sec#187/234
Value
P/B	1.05x	KR#1,518/2,436 Sec#99/234
P/S	63.83x	KR#2,376/2,436 Sec#201/234
FCF Yield	-51.68%	KR—/2,436 Sec—/234
Profitability
ROE	-40.74%	KR#2,231/2,436 Sec#189/234
ROA	-34.15%	KR#2,324/2,436 Sec#208/234
Op. Margin	-2062.07%	KR#2,397/2,436 Sec#223/234
Revenue Growth	30.69%	KR#468/2,436 Sec#42/234
Financial Health
Debt Ratio	119.30%	KR#640/2,436 Sec#81/234
Total Debt	8.83B KRW	KR#1,661/2,436 Sec#152/234
FCF	-33.48B KRW	KR#2,020/2,436 Sec#196/234
Cash	10.13B KRW	KR#1,663/2,436 Sec#132/234
Current Ratio	3.37x	KR#537/2,436 Sec#80/234
Performance
1Y Return	-77.51%	KR#2,392/2,436 Sec#233/234
1M Return	1.13%	KR#932/2,436 Sec#76/234
From 52W High	-84.06%	KR#2,396/2,436 Sec#230/234
1Y MDD	-88.33%	KR#2,409/2,436 Sec#231/234
Trading
Volume	748,679 shares	KR#205/2,436 Sec#12/234
Foreign Own.	5.60%	KR#748/2,436 Sec#72/234
Per Share
EPS	-359 KRW	KR—/2,436 Sec—/234
BPS	687 KRW	KR#2,354/2,436 Sec#221/234

Company Info

CEO 신영기

Employees 44

Founded 2007

HQ 서울특별시 구로구, KR

Website www.abionbio.com

동사는 2007년 설립된 신약 연구개발 바이오 벤처로, 2021년 코스닥에 특례상장함. 동사는 비소세포폐암 항암치료제 ABN401, 클라우딘3 항체 플랫폼 ABN501, 항체-사이토카인 융합단백질 ABN202, 인터페론-베타 기반 치료제 ABN101 등을 보유함. 정밀의료 연구를 통해 맞춤형 치료를 가능하게 하며, 신약의 임상 성공과 상업적 가치를 극대화하고 있음. 에이비온는 2007년에 설립되었으며 서울특별시 구로구에 본사를 두고 있습니다.